A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients With Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Seviteronel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Innocrin Pharmaceuticals
- 28 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.